Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials

Main Article Content

Jo Lambert
Carle Paul
Alice Gottlieb
Yves Poulin

Keywords

deucravacitinib, plaque psoriasis, tyroskine kinase inhibitor

Abstract

N/A

References

1. Burke JR, et al. Sci Transl Med. 2019;11:eaaw1736

2. SOTYKTU™ (deucravacitinib) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; September 2022

3. Armstrong AW, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02256-3. doi: 10.1016/j.jaad.2022.07.002. Online ahead of print

4. Strober B, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02643-3. doi: 10.1016/j.jaad.2022.08.061. Online ahead of print.

5. Warren RB, et al. Presented at the European Academy of Dermatology and Venereology 30th Congress; September 29—October 2, 2021

6. Warren RB, et al. Presented at the European Academy of Dermatology and Venereology Spring Symposium; May 12–14, 2022

7. Wrobleski ST, et al. J Med Chem. 2019;62:8973-8995

8. Walsh JA, et al. J Am Acad Dermatol. 2013;69:931-937.

9. Merola JF, et al. J Invest Dermatol. 2018;138:1955-1961.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 > >>